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Metabolomics:
What’s Happening
Downstreamof DNA
T
he decoding of the human genome gave rise to genomics and pro-
teomics—“global” studies of genes and proteins, respectively—which
are often touted in terms of their enormous clinical potential. In the midst of
a growing shift toward translational studies in today’s biomedical research
scene, yet another “-omics” science has come to the fore. The science is called
metabolomics, and its protagonists say it offers a cheap, rapid, and effective
way to diagnose illness and monitor patient therapy. 
Metabolomics is the study of metabolite profiles in biological samples, par-
ticularly urine, saliva, and blood plasma; scientists are interested in all, rather
than some, of the metabolites in a given sample. Metabolites are the by-prod-
ucts of metabolism, which is itself the process of converting food energy to
mechanical energy or heat. The number of different metabolites in the human
is unknown; estimates range from a low of 2,000–3,000 to a high of around
20,000, compared to an estimated 30,000 genes and 100,000 proteins. Of par-
ticular interest to metabolomics researchers are small, low-molecular-weight
compounds that serve as substrates and products in various metabolic path-
ways. These “small molecules,” as they are called, include compounds such as
lipids, sugars, and amino acids that can provide important clues about the indi-
vidual’s health. 
The metabolome—the collection of all metabolites in a cell at a point in
time—reveals much about that cell’s physiological state at the time of sam-
pling, and humans have trillions of cells of many different types, all with
potentially different metabolomes. Whereas genes and proteins set the stage for
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al activity is at the metabolite level: cell sig-
naling, energy transfer, and cell-to-cell
communication are all regulated by metabo-
lites. Furthermore, gene and protein expres-
sion are closely linked, but metabolite
behavior more closely reflects the actual cel-
lular environment, which is itself dependent
on nutrition, drug and pol-
lutant exposures, and
other exogenous factors
that influence health.
Explains Bill Lasley, a
professor in the De-
partment of Population
Health and Reproduc-
tion at the University of
California (UC), Davis,
“Genomics and proteo-
mics tell you what might
happen, but metabolo-
mics tells you what actu-
ally did happen.” 
As in the other “-omics,”
metabolomics data are gathered with high-
throughput methods; nuclear magnetic res-
onance (NMR) spectroscopy and mass
spectroscopy (MS) using robotic automa-
tion are the dominant analytical techniques
used in the field today. “Metabolomics is a
beautiful approach for rapidly acquiring a
vast amount of information about the
molecular composition of a sample,” says
Mark Viant, a research fellow in the School
of Biosciences at the University of Birming-
ham, United Kingdom. “If you have a dis-
ease, it’s likely that your metabolism is going
to be affected. The same is true if you get hit
with a toxicant. To be honest, the diagnostic
potential is staggering.”
Other researchers apparently agree:
metabolomics research activities are now
becoming more widespread. The NIH
Roadmap for Medical Research, a broad set
of initiatives intended to focus the organiza-
tion’s agenda for the next several years,
includes an initiative called Metabolomics
Technology Development, which is headed
by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK).
This initiative, currently in the planning
stages, will fund several extramural research
projects this year, says Maren Laughlin, who
directs the NIDDK Metabolism and Struc-
tural Biology Program. A new international
association established to promote the field,
the Metabolomics Society, was announced
in March 2004. This international organiza-
tion of experts from academia, government,
and industry is headed by Rima Kaddurah-
Daouk, cofounder and vice president for
biological research at Metabolon, a compa-
ny that applies metabolomics techniques to
clinical uses. According to Kaddurah-
Daouk, the society will bring together lead-
ers from different disciplines with the
ultimate goal of building the metabolomics
technology and integrating metabolomics
with the broader universe of systems biolo-
gy. “The activities included under the
umbrella of the Metabolomics Society will
encompass metabolic profiling, metabolite
flux analysis, biochemical modeling, and
more,” she says.
Industry research is also on the rise, as
pharmaceutical and biotechnology compa-
nies investigate metabolite profiles as
potential tools for drug development. Their
efforts have been guided in part by
researchers at London University’s Imperial
College of Science, Technology, and Medi-
cine, including Jeremy Nicholson, a profes-
sor of biological chemistry who is widely
regarded as one of the field’s leading figures.
Nicholson was among the first to apply the
tools of metabolite analysis—first NMR
and now also MS—to the assessment of
metabolite changes in biofluids over time. 
A Debate over Terms
Nicholson refers to the field as “metabo-
nomics”—the term he and his colleagues
coined in 1996 to describe studies of
metabolite profiles in the biofluids of whole
organisms. “Metabonomics” specifically
covers the integrated approach of looking at
the effects of all the cellular metabolomes at
one time, says Nicholson. 
This research had actually been ongoing
since the late 1980s, explains John Lindon, a
visiting professor at Imperial College and one
of Nicholson’s long-time collaborators. “We
did the first crucial analysis back in 1988,”
Lindon says. “This was analysis of NMR
spectra from rat urine given different toxi-
cants using pattern recogni-
tion techniques. We
immediately realized the
power of the approach
and have been working
in the field ever since.”
Lindon says the term
“metabonomics” comple-
ments “genomics” and
“proteomics.” 
In recent years, ”meta-
bolomics,” with its greater
similarity to “metabolite,”
has emerged as the more
widespread term, partic-
ularly at the NIH and
among its affiliated scientists. But Nicholson
says metabolomics can be regarded as a sub-
set of metabonomics—the latter, he says,
covers classifying samples, understanding
biochemical mechanisms, identifying bio-
markers, quantitatively analyzing concen-
trations and fluxes, and probing molecular
dynamics and interactions. 
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Genomics and proteomics tell you what might
happen, but metabolomics tells you
what actually did happen.
–Bill Lasley
University of California,Davis
If you have a disease, it’s likely that your
metabolism is going to be affected. The same 
is true if you get hit with a toxicant. To be
honest,the diagnostic potential is staggering.
–Mark Viant
University of BirminghamEnvironmental Health Perspectives • VOLUME 112 | NUMBER 7 | May 2004 A 413
Confusion over what to call the field is
a persistent problem; sources interviewed
for this article universally described the
debate as a distraction from the science
itself that must be resolved. Kaddurah-
Daouk says the Metabolomics Society will
dedicate itself in the early stages to defining
appropriate terminology as a top priority.
“We respect the niche that Nicholson wants
to define as ‘metabonomics,’ which we
believe will form a subset of the broader
field,” she says. 
Metabolite Biomarkers
In the long run, scientists are looking to
metabolomics to fill important gaps in sys-
tems biology, a research paradigm focused
on all the interconnected molecular path-
ways in cells and organisms. Short-term
clinical goals for the field are more con-
cerned with the search for biomarkers, or
molecular indicators of pathology. 
Individual metabolites have already
been used as disease biomarkers for years.
Elevated glucose, for in-
stance, is indicative of
diabetes mellitus. And
cholesterol is a metabo-
lite long associated with
heart disease and stroke.
Metabolomics enables
the identification of bio-
markers based on entire
groupings of metabolites
that are up- or downreg-
ulated in unison under
specific conditions. 
Bruce Hammock, a
distinguished professor
of entomology in the UC
Davis Cancer Research Center and director
of the NIEHS–UC Davis Superfund Basic
Research Program, says these metabolic pro-
files could broaden insights into the cause of
disease. “High cholesterol might tell you
that you have a problem, but if you supple-
ment with five other measures, you could
determine why you have the problem,” he
explains. “We might be able to say it’s
because your transport proteins are poor, or
because you’re eating too much fat, and so
on. The profile will give you knowledge and
information rather than just data.” 
Some experts believe metabolomics
could provide clinical uses sooner than either
genomics or proteomics. Several factors
contribute to this view. First, metabolite
profiles are comparatively cheap to generate,
assuming the requisite instruments have
already been purchased—once purchase
costs are subtracted, the standard instru-
ments, particularly NMR, can identify a
sample’s metabolite spectrum quickly for a
few dollars. In contrast, the DNA microar-
rays used in genomics research cost hun-
dreds to thousands of dollars and are often
unavailable to clinicians, while protein
analysis is time-consuming and hindered by
the much larger size and complexity of the
molecules, which have more functional
components. Furthermore, the functions of
most genes and proteins remain unknown,
whereas metabolites can often be assigned to
particular tissues and disease categories,
which allows fairly easy extrapolation of
their functions. 
Finally, metabolomics is noninvasive
and allows for repeated sampling over time.
Gene expression profiles, on the other
hand, can be generated only from cells that
have been impacted by disease, such as
tumor cells. Proteins can be obtained from
tissues and blood plasma, but not from
urine, where they generally only appear as
symptoms of illness. But metabolites are
present in tissues, blood, saliva, and urine.
Some biofluid samples can be linked to
anomalies in particular tissues. For in-
stance, urine is more likely
to reflect renal disease,
whereas saliva may more
accurately reflect lung
disease.
Metabolomic bio-
markers do have their
limitations, however.
Donald Robertson, a
scientist at Pfizer, says
that in some cases meta-
bolic responses—which
vary greatly in terms of
their dynamic range—
are so far removed from
the source of pathology
that they are almost impossible to interpret.
“Usually drugs or disease unleash a cascade
of biomolecular effects throughout the
body,” he explains. “Many of these are sub-
tle and below analytical detection limits.”
But Robertson adds that most metabolic
changes could be detected if researchers
knew what to look for. 
In a sense, Robertson says, the limita-
tions of metabolomics are the exact oppo-
site of those posed by genomics. Whereas
the genetic source of a disease might be too
far “upstream” of the pathology to identify,
metabolic changes might be too far “down-
stream,” and diluted by the activities of
proteins, the environment, and other
intermediate biochemical events. Metabo-
lomic profiles are also subject to random
fluctuations, and can be influenced by diet,
sleep patterns, age, smoking, and many
other variables that mask the effects of dis-
ease or toxicity. Teasing biomarkers out
from this background noise is a complex
analytical and statistical challenge, scientists
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The [metabolic] profile will give you knowledge
and information rather than just data.
–Bruce Hammock
University of California, Davis
Looking at the genome won’t tell you
much about the downstream function, but
looking at the metabolome won’t tell you
much about the underlying regulation. It’s
the whole integration that’s important.
–Teresa Fan
University of Louisville, Kentuckysay, although one that ultimately should be
achievable. 
It is for these reasons and others, stresses
Teresa Fan, an associate professor of chem-
istry at the University of Louisville, Ken-
tucky, that scientists should view all the
“-omics” sciences as complementary. “The
bottom line is that you’re not
going to get the full pic-
ture with any one ‘-omic’
technique,” she says.
“Looking at the genome
won’t tell you much
about the downstream
function, but looking at
the metabolome won’t
tell you much about the
underlying regulation. It’s
the whole integration
that’s important.” 
Metabolomics and
Environmental Health
Metabolomics applications in environ-
mental health, now in their early stages,
may yield important benefits to the field.
Some scientists believe metabolomics can
fill key data gaps in environmental toxi-
cology and enable more informed risk
assessment decision making. And because
metabolomics studies may yield early-
stage toxicity screens, the science could
lessen the number of animals needed for
research.
There currently are a few different
environmental health projects going on in
several research settings. Lasley, for in-
stance, is using metabolomics to investigate
how dioxin and other endocrine-disrupting
compounds alter lipid chemistry. And in
collaboration with the NIEHS, scientists
at the biotechnology company Paradigm
Genetics are investigating metabolomic
changes in animals following exposure to
acetaminophen.
Brenda Weis, Toxicogenomics Research
Consortium coordinator for the NIEHS,
organized a conference on metabolomics
and environmental health that convened at
the institute last May. With equal partici-
pation from industry, academia, and the
government, the conference defined the
state of the science for metabolomics. A
brief write-up of the meeting highlights
was published in the October 2003 issue of
EHP, with a full meeting report expected
this year. According to Weiss, conference
participants explored the issue of whether
metabolomics technologies are ready for
environmental health research applica-
tions, and discussed appropriate strategies
for developing the science in this respect.
Their conclusions highlight a set of needs
for advancing the technology: namely,
databases, bioinformatics tools, and mul-
tidisciplinary teams and training, among
others.
Despite this apparent forward move-
ment, Weis says the field of environmental
health has yet to embrace metabolomics as
a significant tool for research. The NIEHS’s
activities in the field are minimal, and no
formal extramural projects have been fund-
ed. The attitude of institute scientists, Weis
says, is “cautious,” and they are watching
how the science develops and advances
through developments that are largely
occurring elsewhere. 
However, progress in the NIH Road-
map’s Metabolomics Technology Devel-
opment initiative is of particular interest
to the NIEHS, Weis adds. This initiative
was designed with input from the insti-
tute, which helped prepare the request for
applications with an eye toward technology
innovations. Now, Weis says, institute sci-
entists want to see what kind of new tech-
nologies emerge from the Roadmap.
“Then we can determine how to build on
the science with specific applications to
environmental health, which really hasn’t
been done yet.” 
Industry Pushes Forward
Today, the bulk of progress in metabolomics
is coming out of industry. Perhaps the
biggest venture in the field—funded with
tens of millions of dollars—is a collabora-
tion among Imperial College and the phar-
maceutical companies Pfizer, Pharmacia
(which has since been purchased by Pfizer),
Hoffman-La Roche, Novo
Nordisk, Bristol-Myers
Squibb, and Eli Lilly and
Company. Run by a
steering committee co-
chaired by Lindon and
Nicholson, this group,
known as the Consor-
tium for Metabonomic
Toxicology (COMET),
is developing screening
tools for use in drug
discovery. 
According to Nichol-
son, COMET recently
wrapped up the first
phase of its research: the assessment and pre-
diction of liver and kidney toxicity from
exposure to 80 model compounds in rats
and mice. “We’ve developed a toxicity
screening system based on NMR data that is
at least as good as anything coming out of
genomics or proteomics,” Nicholson says.
“We’re writing up a paper that shows this,
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We need to show the field produces something of
value that can help us understand and monitor
disease. Metabolomics has to show it can be used
to identify new therapeutic targets,streamline drug
discovery, and identify the best drug candidates. 
–Rima Kaddurah-Daouk
Metabolon
The Holy Grail for us is the ability to measure
biologically active concentrations of metabolites
in both a spatial and time-dependent manner.
This will allow us to understand metabolite fluxes
in biochemical pathways.
–Maren Laughlin
National Institute of Diabetes and
Digestive and Kidney DiseasesEnvironmental Health Perspectives • VOLUME 112 | NUMBER 7 | May 2004 A 415
and we’ll be submitting to a peer-reviewed
journal soon.” 
The approach taken by Imperial Col-
lege researchers involves linking peak pat-
terns on the NMR spectrum to toxicity or
drug efficacy using statistical pattern recog-
nition. The COMET researchers rely on
statistical pattern recognition in part
because changes are difficult to compare by
eye. In short, the spectrum becomes a “fin-
gerprint” for the pathology in which the
identity of the actual metabolites is deemed
unnecessary, at least at the outset. “The pat-
tern is what’s important in terms of distin-
guishing normal from abnormal responses,”
Nicholson says. “We use the pattern
recognition intensity signature as a
method of discriminating which parts of
the spectrum are carrying the informa-
tion, and then solve the molecular struc-
tures of the biomarkers.”
Experts in the field generally agree
that fingerprinting is useful in the short
term. Fingerprinting advances metabolomics
by stimulating interest and funding. Fur-
thermore, it generates screening tools for
toxicity evaluation and disease diagnosis
that lay the groundwork for more detailed
studies. 
But researchers must eventually link the
patterns back to biological mechanisms,
Weis says. “If you want to understand the
underlying biology, you have to understand
the peaks,” she explains. “You need to know
the metabolite concentrations, activity, and
structure. It’s not enough to just come up
with a peak and then say, ‘There it is.’ You
need to go one step further to find out
what’s behind it. That’s how you identify
biological pathways.” 
Understanding the underlying biology
is important, Robertson adds, because it
helps to confirm that observed profiles are
relevant to the process of interest. For
example, a drug might cause an animal to
lose weight, producing a metabolite pro-
file that reflects nutritional changes rather
than toxicity. Without this knowledge, a
researcher might erroneously attribute the
profile to the drug’s toxic mechanism. 
The Short-Term Outlook
Metabolomics is in a proof-of-principle
phase at the NIH today. Experts agree the
field is taking off during a period of
“‘-omics’ fatigue” that has fueled a degree
of skepticism among some scientists. Both
genomics and proteomics were heavily
hyped, and there is some concern over the
slow pace of progress in both these fields.
Thus, NIH officials are taking a wait-and-
see approach to metabolomics, funding
small-scale pilot studies designed to pro-
duce concrete results.
Kaddurah-Daouk says metabolomics
must achieve some important short-term
goals in order to garner more funding.
First, scientists must validate that the
technique is robust, reliable, and repro-
ducible. And second, the field must show
that it can generate biomarkers useful for
diagnosing disease and monitoring the
effects of therapy. 
“We need to show the field produces
something of value that can help us
understand and monitor disease,” Kaddu-
rah-Daouk says. “Metabolomics has to
show it can be used to identify new ther-
apeutic targets, streamline drug discovery,
and identify the best drug candidates.
We believe that metabolomics can help in
all these respects, but we have to validate
them one concept at a time.” 
Laughlin says that technical improve-
ments are needed to expand the potential
of metabolomics. Among those targeted
by the Metabolomics Technology Devel-
opment initiative, she says, are advance-
ments that will allow scientists to identify
the biologically active fraction of metabo-
lites, as opposed to those that are
“sequestered” in an inactive state and thus
irrelevant to whichever process is being
studied. 
The ability to determine where
metabolites are located in the cell is also
critically important, Laughlin says. “This
is our biggest challenge,” she says. “We
need  in vivo measurements in specific
areas of the cell. The Holy Grail for us is
the ability to measure biologically active
concentrations of metabolites in both a
spatial and time-dependent manner. This
will allow us to understand metabolite
fluxes in biochemical pathways.”
Many other challenges and needs also
face the field. Scientists universally point to
the need for a curated, public database for
NMR and MS spectra, one that optimally
includes profiles for the wide range of pop-
ulations that make up the human race. Vast
databases such as this are key to managing
metabolite variability, which is influenced
by ethnicity, age, nutrition, and many other
factors; comparable databases such as
GenBank and Swiss-Prot aid genomics
and proteomics researchers in molecular
identification. Of course,
new bioinformatics me-
thods will be needed to
wade through these
enormous data sets. The
need for innovative
advances in bioinformat-
ics is particularly acute
with respect to integrat-
ing metabolomics data
with genomics and pro-
teomics—a top priority
for systems biology. 
One of the biggest
risks to the field, accord-
ing to Bruce German, a
professor of food science and technology
at UC Davis, is if people’s expectations of
the information in NMR spectra are too
high. Unlike the genome, which can be
sequenced in its entirety, the metabolome
varies in a tremendous dynamic range, he
says. Promises that NMR will identify all
metabolites and deliver yet another
“-omics” revolution on this basis must be
viewed cautiously, he says. 
“High-resolution NMR of intact
biofluids does not yet identify all the
metabolites,” says German. “But the good
news is that unlike the genome, which
we’re only just now beginning to under-
stand, metabolism is well known to scien-
tists. We’ve spent decades studying
metabolism, but ironically very little of
this has been brought to a diagnostic
application. You could say that metabo-
lism is a mature science looking for a
game to play in.” 
Charles W. Schmidt
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We’ve spent decades studying metabolism, but
ironically very little of this has been brought
to a diagnostic application. You could say that
metabolism is a mature science looking for a
game to play in.
–Bruce German
University of California, Davis